# To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT01529853** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 24 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** SAR156597
- **DRUG:** Placebo (for SAR156597)

## Key facts

- **NCT ID:** NCT01529853
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01529853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01529853, "To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01529853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*